The European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), with the contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), have developed guidelines on myocardial revascularization. The guidelines aim to assist physicians in selecting the best management strategy for patients with coronary artery disease (CAD), considering the impact on outcomes and the risk-benefit ratio of diagnostic or therapeutic means. The guidelines emphasize the importance of risk stratification, the role of the Heart Team in decision-making, and the use of various imaging techniques to assess CAD and ischaemia. The guidelines also address the use of percutaneous coronary intervention (PCI) with drug-eluting stents (DES) versus bare metal stents (BMS), and coronary artery bypass grafting (CABG) versus medical therapy. The guidelines provide recommendations for the treatment of stable CAD, non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and ST-segment elevation myocardial infarction (STEMI), as well as for patients with diabetes, chronic kidney disease, and chronic heart failure. The guidelines also discuss the procedural aspects of CABG and PCI, antithrombotic pharmacotherapy, and secondary prevention strategies. The guidelines are based on a comprehensive review of the available evidence, including randomized clinical trials (RCTs) and observational studies, and are intended to guide clinical practice in a patient-centered, evidence-based manner. The guidelines are endorsed by the ESC and EACTS and are published in the European Heart Journal and the European Journal of Cardio-Thoracic Surgery. The guidelines emphasize the importance of informed consent, the role of the Heart Team in decision-making, and the need for individualized treatment plans based on the patient's clinical presentation, anatomical disease, and functional status. The guidelines also highlight the importance of risk stratification, the use of various scoring systems, and the need for ongoing follow-up and monitoring of patients undergoing revascularization. The guidelines are intended to be used by cardiologists, cardiac surgeons, and other healthcare professionals to provide optimal care for patients with CAD.The European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), with the contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), have developed guidelines on myocardial revascularization. The guidelines aim to assist physicians in selecting the best management strategy for patients with coronary artery disease (CAD), considering the impact on outcomes and the risk-benefit ratio of diagnostic or therapeutic means. The guidelines emphasize the importance of risk stratification, the role of the Heart Team in decision-making, and the use of various imaging techniques to assess CAD and ischaemia. The guidelines also address the use of percutaneous coronary intervention (PCI) with drug-eluting stents (DES) versus bare metal stents (BMS), and coronary artery bypass grafting (CABG) versus medical therapy. The guidelines provide recommendations for the treatment of stable CAD, non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and ST-segment elevation myocardial infarction (STEMI), as well as for patients with diabetes, chronic kidney disease, and chronic heart failure. The guidelines also discuss the procedural aspects of CABG and PCI, antithrombotic pharmacotherapy, and secondary prevention strategies. The guidelines are based on a comprehensive review of the available evidence, including randomized clinical trials (RCTs) and observational studies, and are intended to guide clinical practice in a patient-centered, evidence-based manner. The guidelines are endorsed by the ESC and EACTS and are published in the European Heart Journal and the European Journal of Cardio-Thoracic Surgery. The guidelines emphasize the importance of informed consent, the role of the Heart Team in decision-making, and the need for individualized treatment plans based on the patient's clinical presentation, anatomical disease, and functional status. The guidelines also highlight the importance of risk stratification, the use of various scoring systems, and the need for ongoing follow-up and monitoring of patients undergoing revascularization. The guidelines are intended to be used by cardiologists, cardiac surgeons, and other healthcare professionals to provide optimal care for patients with CAD.